Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA PET Imaging in Advanced HCC Patients Undergoing Immunotherapy
NCT05176223Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of gallium ga-68 gozetotide in hepatocellular carcinoma (HCC), sponsored by Mayo Clinic. Started Jan 2022; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05176223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176223.